Switzerland: Biomanufacturing Lonza Starts New Concept in Biological Manufacturing and Development

Editor: Alexander Stark

Lonza announced the launch of Ibex Solutions which couples flexibility in facility-build-out with tailored business models. Construction began in June with a formal groundbreaking ceremony expected in the second half of 2017.

Related Vendors

Ibex Solutions is a new biological development and manufacturing concept, developed by Lonza.
Ibex Solutions is a new biological development and manufacturing concept, developed by Lonza.
(Source: Lonza)

Visp/Switzerland — According to the company, several hundred new positions are expected to be created. Ibex biomanufacturing comprises a modular, technology-independent development and manufacturing complex capable of supporting activities across multiple technologies — mammalian, microbial, cellular or bio-conjugate. This flexibility gives customers complete freedom in facility design and implementation, and the ability to respond rapidly as their needs evolve, the company claims.

The biomanufacturing complex is integrated into the Visp site with its workforce and service networks. The service includes flexible models to match and adapt to each customer’s expectations and forecasts. The availability of a modular complex means time-to-market can be reduced by twelve months or more.

Lonza’s Pharma & Biotech COO, Marc Funk, commented: “Lonza has been creating innovative manufacturing and production solutions for 120 years, and we are continuing to pioneer clinical and commercial manufacturing in multiple technologies all over the world. We have been working with our partners to understand what we can offer that will really change the game for them, and that’s why we have created Ibex.”

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent

(ID:44818356)